Drug Safety Project

The drug supply chain has become increasingly complex in recent years. Today’s prescription and over-the-counter remedies originate in factories all over the world, moving into American homes through supply chains that can involve numerous processing plants, manufacturers, suppliers, brokers, packagers, and distributors. This increases the risk that substandard or counterfeit medicines could reach patients and contributes to shortages of essential medicines. Pew’s work on drug safety helps to ensure a safe, reliable pharmaceutical manufacturing and distribution system.

Our Work

View All
  • Pharmacy Implementation of the Drug Supply Chain Security Act

    The Drug Supply Chain Security Act (DSCSA) of 2013 created a national system in which companies involved in pharmaceutical distribution work together to safeguard the U.S. pharmaceutical supply and protect consumers from compromised or counterfeit drugs. Pharmacies play a critical role in preventing unsafe products from reaching consumers. Read More

  • Comments to FDA on 503B Quality Standards Draft Guidance

    On September 2, Pew submitted comments to the U.S. Food and Drug Administration in response to draft guidance on the implementation of Title I of the Drug Quality and Security Act. The comments highlight the need for more robust safeguards when compounding occurs on a larger scale and reference the Pew commissioned report “Ensuring the Safety of Compounded Drugs: Study highlights key... Read More

  • Pew and Partners Comment on FDA’s Suspect Product Guidance

    On Monday, August 11, The Pew Charitable Trusts submitted comments on draft guidance documents from the U.S. Food and Drug Administration on how supply chain partners will identify and notify other partners of “suspect product,” part of Title II of the Drug Quality and Security Act, Drug Supply Chain Security Act. Read More

Media Contact

Sarah Carroll

Associate, Communications

202.540.6714